Fusen Pharmaceutical Company Limited provided unaudited consolidated earnings guidance for the year ended 31 December 2019. For the period, the Group is expected to record a decrease in the profit attributable to owners of the company for fiscal year 2019 by over 45%, as compared to the profit attributable to owners of the Company of approximately RMB 102 million for the year ended 31 December 2018.